GlassScriptPhysician profile
Susannah M Green
NPI 1992198550
$1,368.58
in general payments reported to CMS, 2019-2025
23 companies · $669 in 2025
The $669 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $36.00 · 2023: $241 · 2024: $422 · 2025: $669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,332.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $213.31 | 2023-2025 | |
| Lilly USA, LLC | $194.22 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $124.97 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Abbott Laboratories | $103.68 | 2024-2025 | Freestyle Libre 3 |
| Pfizer INC. | $92.81 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.96 | 2023-2025 | Jardiance, Tradjenta, Synjardy |
| Exact Sciences Corporation | $72.81 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $72.74 | 2025 | Otezla, Repatha, Evenity |
| Novo Nordisk INC | $63.49 | 2023-2024 | Rybelsus, Ozempic |
| Phathom Pharmaceuticals, INC. | $58.01 | 2024-2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $55.49 | 2023-2024 | Xarelto |
| Ibsa Pharma INC. | $40.38 | 2023-2024 | Tirosint, Licart, Tirosint |
| Astellas Pharma US INC | $27.26 | 2025 | Veozah |
| Alexion Pharmaceuticals, INC. | $23.75 | 2025 | Strensiq |
| Insulet Corporation | $23.21 | 2025 | Omnipod |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $21.27 | 2022 | |
| Boston Scientific Corporation | $17.27 | 2025 | Watchman Flx |
| Sumitomo Pharma America, INC. | $15.46 | 2023 | Gemtesa |
| Merck Sharp & Dohme LLC | $15.44 | 2023 | Belsomra |
| Axsome Therapeutics, INC. | $15.18 | 2025 | Auvelity |
| Novartis Pharmaceuticals Corporation | $15.09 | 2025 | |
| Esperion Therapeutics, INC. | $15.05 | 2025 | Nexletol |
| Opko Pharmaceuticals, LLC | $14.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susannah Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.